Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.
What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma’s nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.